Genomic technology pays off: Bayer and Millennium expand research program
New therapeutic areas are thrombosis, urinary incontinence and prostate hyperplasia
20-Sep-2001 -
Bayer and Millennium
Pharmaceuticals, Cambridge, Massachusetts, have
decided to expand their highly successful research
alliance. Work will now also focus on the identification
of important new drug targets relevant to thrombosis,
urinary incontinence and benign prostatic hypertrophy.
The ...
Bayer
benign prostatic hyperplasia
benign prostatic hypertrophy
+9